Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07400952
PHASE2

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Sponsor: Glaukos Corporation

View on ClinicalTrials.gov

Summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Official title: Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-12-23

Completion Date

2027-04

Last Updated

2026-02-10

Healthy Volunteers

No

Conditions

Interventions

DRUG

GLK-221 Ophthalmic Solution

GLK-221 Ophthalmic Solution administered twice daily to both eyes

DRUG

Placebo Ophthalmic Solution

Placebo Ophthalmic Solution administered twice daily to both eyes

Locations (1)

Glaukos Clinical Study Site

Westerville, Ohio, United States